Hyperopic LASEK treatments with mitomycin C using the SCHWIND AMARIS.
OBJECTIVE
To investigate the outcomes of hyperopic laser epithelial keratomileusis (LASEK) with mitomycin C (MMC) using the SCHWIND AMARIS platform.


METHODS
Prospective study of 28 eyes of 14 patients. Mean preoperative manifest spherical equivalent refraction was +2.71±0.72 diopters (D) (range: +1.50 to +4.50 D). All eyes underwent LASEK with an Aberration-Free™ algorithm with the SCHWIND AMARIS followed by a 35-second application of MMC with a 6.7-mm optical zone size.


RESULTS
At 1 year, mean manifest spherical equivalent refraction was 0.03±0.30 D (range: -0.53 to +0.50 D), with 13 eyes within -0.13 to +0.13 D and all 28 eyes within ±0.50 D. Mean uncorrected distance visual acuity was -0.03±0.09 logMAR, and the efficacy and safety indices were 1, respectively, at 1 year. The postoperative manifest spherical equivalent refraction was stable between 1 and 3 months and 1 year.


CONCLUSIONS
Hyperopic LASEK with MMC using the SCHWIND AMARIS provided good outcomes in terms of accuracy, efficacy, safety, and stability.
School of Biomedical Sciences and Cathedral Eye Clinic, University of Ulster, Coleraine, Northern Ireland, United Kingdom.
Colm
C
McAlinden
Eirini
E
Skiadaresi
Jonathan E
JE
Moore
D000328:Adult; D019573:Epithelium, Corneal / Q000187:drug effects / Q000601:surgery*; D004867:Equipment Design; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D006956:Hyperopia / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D007432:Intraoperative Period; D049008:Keratectomy, Subepithelial, Laser-Assisted / Q000295:instrumentation*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D012029:Refraction, Ocular; D016896:Treatment Outcome
D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D016685:Mitomycin